| Summary of Significant Accounting Policies | Note 3 – Summary of Significant Accounting
Policies Basis of presentation and consolidation The Company has prepared the accompanying unaudited
condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”)
and the standards of accounting measurement set forth in the Interim Reporting Topic of the Financial Accounting Standards Board (“FASB”)
Accounting Standards Codification (“ASC”). Certain information and note disclosures normally included in annual financial
statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have
been condensed or omitted, although the Company believes that the disclosures made are adequate to make the information not misleading.
The Company recommends that the unaudited condensed consolidated financial statements be read in conjunction with the audited consolidated
financial statements and the notes thereto included in the Company’s latest Annual Report on Form 10-K. In the opinion of management,
all adjustments that are necessary for a fair presentation of the Company’s financial position for the periods presented have been
reflected. All adjustments are of a normal, recurring nature, unless otherwise stated. The interim condensed consolidated results of operations
are not necessarily indicative of the results that may occur for the full fiscal year. The December 31, 2022 consolidated balance sheet
included herein was derived from the audited consolidated financial statements, but does not include all disclosures including notes required
by GAAP for complete financial statements. The accompanying unaudited condensed consolidated
financial statements include the accounts of OpGen and its wholly owned subsidiaries as of and for the three months ended March 31, 2023;
all intercompany transactions and balances have been eliminated. Foreign currency The Company has subsidiaries located in Holzgerlingen,
Germany and Vienna, Austria, each of which use currencies other than the U.S. dollar as their functional currency. As a result, all assets
and liabilities of the subsidiaries are translated into U.S. dollars based on exchange rates at the end of the reporting period. Income
and expense items are translated at the average exchange rates prevailing during the reporting period. Translation adjustments are reported
in accumulated other comprehensive income (loss), a component of stockholders’ equity. Foreign currency translation adjustments
are the sole component of accumulated other comprehensive income (loss) at March 31, 2023 and December 31, 2022. Foreign currency transaction gains and losses, excluding
gains and losses on intercompany balances where there is no current intent to settle such amounts in the foreseeable future, are included
in the determination of net loss. Unless otherwise noted, all references to “$” or “dollar” refer to the United
States dollar. Use of estimates In preparing financial statements in conformity with
GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting period. In the accompanying unaudited condensed consolidated financial statements, estimates are used for, but not limited
to, liquidity assumptions, revenue recognition, inducement expense related to warrant repricing, stock-based compensation, allowances
for doubtful accounts and inventory obsolescence, discount rates used to discount unpaid lease payments to present values, valuation of
derivative financial instruments measured at fair value on a recurring basis, deferred tax assets and liabilities and related valuation
allowance, determining the fair value of assets acquired and liabilities assumed in business combinations, the estimated useful lives
of long-lived assets, and the recoverability of long-lived assets. Actual results could differ from those estimates. Fair value of financial instruments Financial instruments classified as current assets
and liabilities (including cash and cash equivalents, receivables, accounts payable, deferred revenue and short-term notes) are carried
at cost, which approximates fair value, because of the short-term maturities of those instruments. Cash and cash equivalents and restricted cash The Company considers all highly liquid instruments
with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial
institutions in which the balances occasionally exceed the Federal Deposit Insurance Corporation (“FDIC”) insured limit of
$250,000. On March 10, 2023, the Company learned that Silicon Valley Bank (“SVB”), the Company’s primary bank at the
time, was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation
as receiver. The Company did not experience any losses in such accounts, but since the Company was exposed to credit risk with the failure
of SVB, management diversified the Company’s holdings to minimize credit risk in the future. At March 31, 2023 and December 31, 2022, the Company
had funds totaling $497,055 and $495,629, respectively, which are required as collateral for letters of credit benefiting its landlords
and for credit card processors. These funds are reflected in other noncurrent assets on the accompanying unaudited condensed consolidated
balance sheets. The following table provides a reconciliation of cash
and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts
shown in the condensed consolidated statements of cash flows:
March 31, 2023 December 31, 2022 March 31, 2022 December 31, 2021
Cash and cash equivalents $ 7,039,375 $ 7,440,030 $ 30,653,410 $ 36,080,392
Restricted cash 497,055 495,629 468,041 551,794
Total cash and cash equivalents and restricted cash in the condensed consolidated statements of cash flows $ 7,536,430 $ 7,935,659 $ 31,121,451 $ 36,632,186 Accounts receivable The Company’s accounts receivable result from
revenues earned but not yet collected from customers. Credit is extended based on an evaluation of a customer’s financial condition
and, generally, collateral is not required. Accounts receivable are due within 30 to 90 days and are stated at amounts due from customers.
The Company evaluates if an allowance is necessary by considering a number of factors, including the length of time accounts receivable
are past due, the Company’s previous loss history and the customer’s current ability to pay its obligation. If amounts become
uncollectible, they are charged to operations when that determination is made. The allowance for doubtful accounts was $0 as of March
31, 2023 and December 31, 2022, respectively. At March 31, 2023, the Company had accounts receivable
from two customers which individually represented 42% and 13% of total accounts receivable, respectively. At December 31, 2022, the Company
had accounts receivable from two customers which individually represented 41% and 21% of total accounts receivable, respectively. For
the three months ended March 31, 2023, revenue earned from two customers represented 46% and 19% of total revenues, respectively. For
the three months ended March 31, 2022, revenue earned from three customers represented 27%, 27% and 12% of total revenues, respectively. Inventory Inventories are valued using the first-in, first-out
cost method and stated at the lower of cost or net realizable value and consist of the following:
March 31, 2023 December 31, 2022
Raw materials and supplies $ 1,259,859 $ 1,011,476
Work-in-process 33,245 37,445
Finished goods 2,351,453 2,596,830
Total $ 3,644,557 $ 3,645,751 Inventory includes Unyvero system instruments,
Unyvero cartridges, reagents and components for Unyvero and Acuitas kits, and reagents and supplies used for the Company’s laboratory
services. The Company periodically reviews inventory quantities
on hand and analyzes the provision for excess and obsolete inventory based primarily on product expiration dating and its estimated sales
forecast, which is based on sales history and anticipated future demand. The Company’s estimates of future product demand may not
be accurate, and it may understate or overstate the provision required for excess and obsolete inventory. Accordingly, any significant
unanticipated changes in demand could have a significant impact on the value of the Company’s inventory and results of operations.
Based on the Company’s assumptions and estimates, inventory reserves for obsolescence, expirations, and slow-moving inventory were
$1,974,030 and $1,694,843 at March 31, 2023 and December 31, 2022, respectively. The Company classifies finished good inventory it
does not expect to sell or use in clinical studies within 12 months of the unaudited condensed consolidated balance sheets date as strategic
inventory, a non-current asset. Long-lived assets Property and equipment Property and equipment are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets
to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be
generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for
which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying
amount of assets exceeds the fair value of the assets. During the three months ended March 31, 2023 and 2022, the Company determined that
its property and equipment were not impaired. Leases The Company determines if an arrangement is a
lease at inception. For leases where the Company is the lessee, right-of-use (“ROU”) assets represent the Company’s
right to use the underlying asset for the term of the lease and the lease liabilities represent an obligation to make lease payments arising
from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future
lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement
date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease
payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to
extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company’s lease agreements
generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants. Lease expense for operating leases is recognized
on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation
expense and interest expense using the effective interest method of recognition. The Company has made certain accounting policy elections
whereby the Company (i) does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12 months
or less) and (ii) combines lease and non-lease elements of our operating leases. ROU assets ROU assets are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated
by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which the
Company can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying
amount of assets exceeds the fair value of the assets. The Company did not identify any impaired ROU assets for three months ended March
31, 2023 and 2022. Intangible assets As of March 31, 2023, the Company’s intangible
assets with net balances are all finite-lived. Finite-lived and indefinite-lived intangible assets Intangible assets include trademarks, developed technology
and software, In-Process Research & Development (“IPR&D”), and customer relationships and consisted of the following
as of March 31, 2023 and December 31, 2022:
March 31, 2023 December 31, 2022
Subsidiary Cost Accumulated Amortization and Impairment Effect of Foreign Exchange Rates Net Balance Accumulated Amortization and Impairment Effect of Foreign Exchange Rates Net Balance
Trademarks and tradenames Curetis $ 1,768,000 $ (521,674 ) $ (29,101 ) $ 1,217,225 $ (469,011 ) $ (62,520 ) $ 1,236,469
Distributor relationships Curetis 2,362,000 (464,633 ) (38,879 ) 1,858,488 (417,728 ) (83,525 ) 1,860,747
A50 – Developed technology Curetis 349,000 (147,126 ) (5,744 ) 196,130 (132,273 ) (12,342 ) 204,385
Ares – Developed technology Ares Genetics 5,333,000 (1,123,957 ) (82,553 ) 4,126,490 (1,010,495 ) (183,132 ) 4,139,373
A30 – In-Process Research & Development Curetis 5,706,000 (5,612,078 ) (93,922 ) — (5,407,699 ) (298,301 ) —
$ 15,518,000 $ (7,869,468 ) $ (250,199 ) $ 7,398,333 $ (7,437,206 ) $ (639,820 ) $ 7,440,974 Identifiable intangible assets are amortized on a
straight-line basis over their estimated useful lives. The estimated useful lives of the intangibles are:
Estimated
Useful Life
Trademarks and tradenames 10 years
Customer/distributor relationships 15 years
A50 – Developed technology 7 years
Ares – Developed technology 14 years
A30 – Acquired in-process research & development Indefinite Acquired IPR&D represents the fair value assigned
to those research and development projects that were acquired in a business combination for which the related products have not received
regulatory approval and have no alternative future use. IPR&D is capitalized at its fair value as an indefinite-lived intangible asset,
and any development costs incurred after the acquisition are expensed as incurred. Upon achieving regulatory approval or commercial viability
for the related product, the indefinite-lived intangible asset is accounted for as a finite-lived asset and is amortized on a straight-line
basis over the estimated useful life. If the project is not completed or is terminated or abandoned, the Company may have an impairment
related to the IPR&D which is charged to expense. Indefinite-lived intangible assets are tested for impairment annually and whenever
events or changes in circumstances indicate that the carrying amount may be impaired. Impairment is calculated as the excess of the asset’s
carrying value over its fair value. During the Company’s annual impairment test for its IPR&D intangible asset at December 31,
2022, it was determined that the infinite-lived intangible asset was impaired because although the Company has an ongoing collaboration
utilizing the intangible asset, at the time, the contracted cash flow associated with this collaboration and projected future cash flows
did not support the carrying amount. As a result, the Company recorded an impairment charge in the amount of $5,407,699 for the year ended
December 31, 2022. The Company
reviews the useful lives of intangible assets when events or changes in circumstances occur which may potentially impact the estimated
useful life of the intangible assets. Total amortization expense of intangible assets was
$186,377 and $192,025 for the three months ended March 31, 2023 and 2022, respectively. Expected future amortization of intangible assets
is as follows:
Year Ending December 31,
2023 (April to December) $ 564,347
2024 752,463
2025 752,463
2026 752,463
2027 715,644
Thereafter 3,860,953
Total $ 7,398,333 In accordance with
ASC 360-10, Property, Plant and Equipment Goodwill Goodwill represents the excess of the purchase
price paid when the Company acquired AdvanDx, Inc. in July 2015 and Curetis in April 2020, over the fair values of the acquired tangible
or intangible assets and assumed liabilities. Goodwill is not tax deductible in any relevant jurisdictions. The Company conducts an impairment
test of goodwill on an annual basis and will also conduct tests if events occur or circumstances change that would, more likely than not,
reduce the Company’s fair value below its net equity value. During the year ended December 31, 2022, the Company performed qualitative
and quantitative analyses, assessing trends in market capitalization, current and future cash flows, revenue growth rates, and the impact
of global unrest and the COVID-19 pandemic on the Company and its performance. Based on the analysis performed, and primarily due to changes
in the Company’s stock price and market capitalization in the third quarter of 2022, it was determined that goodwill was impaired.
As a result, the Company recorded a goodwill impairment charge in the full amount of $6,940,549 for the year ended December 31, 2022. Revenue recognition The Company derives revenues from (i) the sale of
Unyvero Application cartridges, Unyvero instruments, SARS CoV-2 tests, Acuitas AMR Gene Panel test products, (ii) providing laboratory
services, (iii) providing collaboration services (e.g., with the Foundation for Innovative New Diagnostics (FIND) on the Unyvero A30 platform)
including funded software and license arrangements, and (iv) granting access to subsets of the proprietary ARESdb data asset. The Company analyzes contracts to determine the appropriate
revenue recognition using the following steps: (i) identification of contracts with customers, (ii) identification of distinct performance
obligations in the contract, (iii) determination of contract transaction price, (iv) allocation of contract transaction price to the performance
obligations and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenues upon the satisfaction
of its performance obligation (upon transfer of control of promised goods or services to our customers) in an amount that reflects the
consideration to which it expects to be entitled in exchange for those goods or services. The Company defers incremental costs of obtaining
a customer contract and amortizes the deferred costs over the period that the goods and services are transferred to the customer. The
Company had no material incremental costs to obtain customer contracts in any period presented. Deferred revenue results from amounts billed in advance
to customers or cash received from customers in advance of services being provided. Government
grant agreements and research incentives From time to
time, the Company may enter into arrangements with governmental entities for the purposes of obtaining funding for research and development
activities. The Company recognizes funding from grants and research incentives received from Austrian government agencies in the condensed
consolidated statements of operations and comprehensive loss in the period during which the related qualifying expenses are incurred,
provided that the conditions under which the grants or incentives were provided have been met. For grants under funding agreements and
for proceeds under research incentive programs, the Company recognizes grant and incentive income in an amount equal to the estimated
qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage. The Company classifies government grants
received under these arrangements as a reduction to the related research and development expense incurred. The Company analyzes each arrangement
on a case-by-case basis. For the three months ended March 31, 2023 and 2022, the Company recognized $133,938 and $108,465 as a reduction
of research and development expense related to government grant arrangements, respectively. The Company had earned but not yet received
$544,489 and $401,436 related to these agreements and incentives included in prepaid expenses and other current assets, as of March 31,
2023 and December 31, 2022, respectively. Research and development costs, net Research and development costs are expensed as incurred.
Research and development costs primarily consist of salaries and related expenses for personnel, other resources, laboratory supplies,
and fees paid to consultants and outside service partners. Stock-based compensation Stock-based compensation expense is recognized at
grant date fair value. The fair value of stock-based compensation to employees and directors is estimated, on the date of grant, using
the Black-Scholes model. For restricted stock awards with a time-based vesting condition, the fair value, which is fixed at the grant
date for purposes of recognizing compensation costs, is determined by reference to the Company’s stock price on the grant date.
The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.
For all time-vesting awards granted, expense is amortized using the straight-line attribution method. The Company accounts for forfeitures
as they occur. Option valuation models, including the Black-Scholes
model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair
value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected
life of the award. Warrants The Company accounts for warrants as either equity-classified
or liability-classified instruments based on an assessment of the instruments’ specific terms and applicable authoritative guidance
in ASC 480, Distinguishing Liabilities from Equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC 815”).
The assessment considers whether the instruments are free standing financial instruments pursuant to ASC 480, meet the definition of a
liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including
whether the instruments are indexed to the Company’s own ordinary shares and whether the instrument holders could potentially require
“net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification.
This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent
period end date while the instruments are outstanding. Income taxes Income taxes are accounted for under the asset and
liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary
differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax
assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized
in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income
tax assets to the amount expected to be realized. Tax benefits are initially recognized in the financial
statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions
are initially, and subsequently, measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon
ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts. The Company had federal net operating loss (“NOL”)
carryforwards of $232,682,072 and $202,015,062 at December 31, 2022 and 2021, respectively. Despite the NOL carryforwards, which began
expiring in 2022, the Company may have state tax requirements. Also, use of the NOL carryforwards may be subject to an annual limitation
as provided by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”). To date, the Company has not performed
a formal study to determine if any of its remaining NOL and credit attributes might be further limited due to the ownership change rules
of Section 382 or Section 383 of the Code. The Company will continue to monitor this matter going forward. There can be no assurance that
the NOL carryforwards will ever be fully utilized. The Company also has foreign NOL carryforwards of
$170,661,923 at December 31, 2022 from their foreign subsidiaries. $162,712,615 of those foreign NOL carryforwards are from the Company’s
operations in Germany. Despite the NOL carryforwards, the Company may have a current and future tax liability due to the nuances of German
tax law around the use of NOLs within a consolidated group. There is no assurance that the NOL carryforwards will ever be fully utilized. Loss per share Basic loss per share is computed by dividing net loss
available to common stockholders by the weighted average number of shares of common stock outstanding during the period. For periods of net income, and when the effects are
not anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted average
number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and
stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method. For periods of net loss, diluted loss per share is
calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of
anti-dilutive shares, consisting of (i) common stock options, (ii) stock purchase warrants, and (iii) unvested restricted stock units
representing the right to acquire shares of common stock which have been excluded from the computation of diluted loss per share, was
6.7 million shares and 1.0 million shares as of March 31, 2023 and 2022, respectively. Adopted accounting pronouncements In May 2021, the FASB issued ASU No. 2021-04, Earnings
Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic
718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) Recently issued accounting standards The Company has evaluated all other issued and unadopted
ASUs and believes the adoption of these standards will not have a material impact on its results of operations, financial position or
cash flows. |
